When.com Web Search

  1. Ads

    related to: new drugs on the market for cancer diagnosis

Search results

  1. Results From The WOW.Com Content Network
  2. Merck-AstraZeneca breast cancer drug reduces risk of ... - AOL

    www.aol.com/finance/merck-astrazeneca-breast...

    A drug already FDA-approved for people with a rare form of breast cancer has now been shown to improve patients’ long-term survival, new clinical trial data suggest.. Lynparza (olaparib), a ...

  3. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.

  4. Pediatric cancer drugs in shortage as drug supply ... - AOL

    www.aol.com/news/pediatric-cancer-drugs-shortage...

    Pediatric cancer doctors are sounding the alarm about a growing shortage of chemotherapy drugs for children. The dwindling supplies add another layer to the ongoing cancer drug shortage crisis ...

  5. Drugmakers to raise US prices on over 250 medicines starting ...

    www.aol.com/news/drugmakers-raise-us-prices-over...

    The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year. Drugmakers to raise US prices on over 250 medicines starting ...

  6. RNA therapeutics - Wikipedia

    en.wikipedia.org/wiki/RNA_Therapeutics

    RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use since the 1990s, with significant success in cancer therapy in the early 2010s. [1] In 2020 and 2021, mRNA vaccines have been developed globally for use in combating the coronavirus disease (COVID-19 pandemic). [2]

  7. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Treatment of adults with locally advanced, unresectable (stage III) non- small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2]